Intellipharmaceutics (IPCI) Reports Q3 Loss of $0.08/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Intellipharmaceutics to Present at Dawson James Securities Growth Stock Conference
October 9, 2015 7:00 AM EDTTORONTO, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq: IPCI) (TSX: I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the Dawson James Securities Growth Stock Conference on October 15, 2015. The presentation will take place at 11:45 A.M. (EDT) in the Wyndham Grand Hotel in Jupiter, Florida.
The presentation may be accessed through the Investor Relations' Events and Presentations section on Intellipharmaceutics' website at... More
Intellipharmaceutics Announces Third Quarter 2015 Results
October 9, 2015 7:00 AM EDTTORONTO, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2015. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
During the three months ended August 31, 2015, the Company continued its focus on the development of its specialty drug product candidates Rexista Oxycodone... More
Intellipharmaceutics to Present at Dawson James Securities Growth Stock Conference
October 9, 2015 7:00 AM EDTTORONTO, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq: IPCI) (TSX: I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the Dawson James Securities Growth Stock Conference on October 15, 2015. The presentation will take place at 11:45 A.M. (EDT) in the Wyndham Grand Hotel in Jupiter, Florida.
The presentation may be accessed through the Investor Relations' Events and Presentations section on Intellipharmaceutics' website at... More
Intellipharmaceutics Announces Third Quarter 2015 Results
October 9, 2015 7:00 AM EDTTORONTO, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2015. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
During the three months ended August 31, 2015, the Company continued its focus on the development of its specialty drug product candidates Rexista Oxycodone... More
